Sourcing & Management of Health Products

Information Notice

The aim of these notices is to provide guidance and advise on how to operationalize in practical terms the consequences of a quality or a safety issue related to a product which has been procured with Global Fund funds. The initial information, which should be stated in the notice, originates from the manufacturer of health products in question and/or confirmed by stringent regulatory mechanisms.

  • Quality Assurance Information Notice 2017-01: Voluntary Recall Initiated by Lupin for Isoniazid Tablets BP 100mg, Batches No A301856, A302231, A302408
    download in English | Español | Français
  • Quality Assurance Information Notice 2016-04: Remedica Product: Sulfadoxine / Pyrimethamine, 500/25 mg, Tablets – Eligibility Reinstated for Procurement with Global Fund Funds
    download in English
  • Quality Assurance Information Notice 2016-03: Hetero Labs Product: Efavirenz, Lamivudine, and Tenofovir, 600/300/300 mg Tablets – No Longer Eligible for Procurement with Global Fund Funds
    download in English | Español | Français
  • Quality Assurance Information Notice 2016-02: Recommendations Regarding the Procurement and the Distribution of Finished Pharmaceutical Products Using Active Pharmaceutical Ingredients Manufactured at IPCA Ratlam Manufacturing Site
    download in English | Español | Français
  • Quality Assurance Information Notice 2016-01: Recommendations Following WHO PQP Suspension of all the Prequalified Products Manufactured by Svizera Labs Private Limited
    download in English